ClinicalTrials.gg
Not yet recruitingNCT07332650Updated Nov 16, 2026

Prospective Clinical Investigation to Evaluate the Safety and Effectiveness of Juläine™ in Improving Gluteal Skin Laxity in Adults.

An interventional study of Poly-L-Lactic Acid (Juläine™) in Skin Quality and Skin Laxity, sponsored by Nordberg Medical AB. Not yet recruiting. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Nordberg Medical AB · Not applicable, Interventional, and Treatment

Updated Nov 16, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study aims to evaluate the safety and effectiveness of Juläine™ (poly-L-lactic acid) injections for the treatment of buttock skin laxity.

Participants will be randomized to an immediate-treatment group or a delayed-treatment group. The immediate-treatment group will receive 2 to 3 treatment sessions over up to 2 months and will be compared with the delayed-treatment group during the control period; the delayed-treatment group will receive the same treatment after the delay.

The primary objective is to assess clinical improvement in buttock skin elasticity 6 months after the last treatment, defined as an increase in skin elasticity measured by a cutometer. Total study participation is up to 16 months, including follow-up.

This multicenter trial will be conducted in Brazil.

Read the detailed description

This is an pivotal, open-label, two-arm, randomized, parallel-group, prospective clinical investigation conducted in Brazil to evaluate the safety and effectiveness of Juläine™ (poly-L-lactic acid) administered as subcutaneous injections for the treatment skin laxity in the buttock (gluteal) region in adults.

A total of 100 participants will be randomized to either an immediate-treatment group or a delayed-treatment group (delayed-start control). Participants in the immediate-treatment group will receive Juläine™ subcutaneous injections in 2 or 3 sessions at Day 0, Day 30, and Day 60. During this initial control period, outcomes in the immediate-treatment group will be compared with those in the delayed-treatment group, which will not receive treatment. After the control period, participants in the delayed-treatment group will receive the same Juläine™ regimen at Day 240, Day 270, and Day 300. Each participant will remain in the study for up to 16 months, excluding screening.

The primary efficacy endpoint is improvement in buttock skin elasticity 6 months after the last injection defined as an increase in global skin elasticity measured by a cutometer, with assessments at screening/baseline and at the primary post-treatment timepoint. The mean change in global skin elasticity measured by cutometer and Global Aesthetic Improvement Scale (GAIS) will also be evaluated, comparing groups during the control period.

Safety will be monitored through the collection of adverse events (AEs) through 240 days after randomization, with comparisons between groups during the control period. Adverse events will also be evaluated through extended follow-up, including up to 180 days in the overall study population and up to 480 days in the immediate-treatment group.

02

Conditions studied

  • Skin Quality
  • Skin Laxity

Keywords

  • Poly-L-lactic acid
  • PLLA
  • Aesthetic
  • Injectable filler
  • Buttocks
  • Gluteal skin laxity
  • Buttock skin laxity
  • Skin elasticity
03

In context

Lead sponsor

Nordberg Medical AB is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 55 years;
  • (BMI) between 18.5 and 24.95 kg/m².
  • Skin laxity of the gluteal region defined as sagging and reduced tightness of the skin.
  • Women of must be willing to abide by the requirements
  • Ability to understand the study and provide , attend follow-up visits, and follow post-injection instructions.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding, or planned pregnancy/lack of adequate (through 8 weeks post-study);
  • Is planning to donate/bank or retrieve eggs (ova, oocytes) or donate sperm during the study or within 8-weeks of the end of participation of the clinical investigation.
  • Active infection, inflammation or lesions at or near the treatment site.
  • Acute infection at screening;
  • History of disease;
  • Immune deficiencies;
  • History of hypertrophic scarring or keloid formation;
  • History of thrombosis in the lower limbs.
  • Previous surgical procedures involving the buttocks
  • Previous treatment with fillers, suspension threads, or fat injection in the treatment area within 18 months before randomization.
  • Previous aesthetic procedures in the treatment area, including radiofrequency, ultrasound, cryotherapy, neurotoxin, laser or light treatment, or chemical peel, within six months before randomization.
  • Previous topical or home therapy for cellulite in the treatment area within three months before randomization.
  • Hemorrhagic disease or ongoing use of antiplatelets/anticoagulant therapy.
  • Treatment with chemotherapy, agents, systemic within 3 months before treatment (inhaled or ophthalmic corticosteroids are allowed).
  • Use of hormonal replacement therapy (HRT) unless the participant has been on a stable dose for at least 3 months prior to screening and does not plan to make any changes to the HRT regimen during the study period.
  • Use of topical corticosteroids, topical prescription retinoids in the treatment area within 1 month of the Baseline visit or systemic retinoid treatment within 6 months of the baseline visit, or plan to receive such treatment.
  • Use of other agents that inhibit collagen production.
  • Known allergy or to any component of the product.
  • History of herpes simplex rashes, malignant skin diseases, or any other serious dermatologic or systemic disease.
  • Presence of any condition that may impair wound healing (e.g., connective tissue disorders, severe malnutrition).
  • Planned or ongoing cosmetic procedures involving the buttocks or surrounding area during the period of clinical investigation.
  • Presence of any skin or local condition in the treatment area that could interfere with treatment administration, participant safety, or evaluation of study endpoints, including scars, fibrosis, tattoos, skin-pigmentation alterations, inflammation, lymphedema, or lipedema.
  • Participants actively taking GLP-1 medications with the intention of achieving additional weight loss (expected >10% during study) will be excluded. Participants on a stable GLP-1 regimen (≥3 months) for diabetes management or weight maintenance, with documented weight stability (±10% in past 6 months) and no planned or expected weight change >10%, may be included.
  • Any other medical or psychological condition that, in the opinion of the investigator, may interfere with participation in clinical research or evaluation of results.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Immediate-treatment group

    Device: Poly-L-Lactic Acid (Juläine™)

  • Other
    Delayed-treatment group (delayed-start control)

    Device: Poly-L-Lactic Acid (Juläine™)

Interventions

  • DevicePoly-L-Lactic Acid (Juläine™)

    Juläine™ is a sterile injectable medical device composed of polylactic acid microspheres.

06

What researchers measure

Primary outcomes

  1. Proportion of participants who achieve an improvement in gluteal skin elasticity

    Proportion of participants achieving a clinically significant reduction in gluteal skin laxity at Day 240 after randomization, whereby a clinically significant reduction ("response") is defined as a relative increase of at least 10% in the gross elasticity measured by cutometer at Day 240 compared to baseline.

    Time frame: Baseline and 240 days after randomization

Secondary outcomes

  1. Mean change in overall skin elasticity

    Mean change in global medial skin elasticity measured by cutometer 180 days after treatment completion.

    Time frame: Baseline and Day 240 after randomization.

  2. Global improvement based on Global Aesthetic Improvement Scale (GAIS) evaluated by investigator

    Proportion of participants with at least a 1-point improvement in GAIS as rated by the investigator at Day 240 after randomization. The GAIS scale values are: 1. Very much improved 2. Much improved 3. Improved 4. No change 5. Worse Where 1 represents the best outcome and 5 represents the worst.

    Time frame: Baseline and Day 240 after randomization.

  3. Global improvement based on Global Aesthetic Improvement Scale (GAIS) evaluated by participant

    Proportion of participants with at least a 1-point improvement in GAIS as rated by the participant at Day 240 after randomization The GAIS scale values are: 1. Very much improved 2. Much improved 3. Improved 4. No change 5. Worse Where 1 represents the best outcome and 5 represents the worst.

    Time frame: Baseline and Day 240 after randomization.

  4. Proportion of adverse events (AEs)

    Proportion of adverse events (AEs) occurring up to 240 days after randomization.

    Time frame: Occurring up to 240 days after the start of treatment, in both groups.

  5. Incidence and severity of Adverse events in the first 30 days

    Incidence and severity of Adverse events in the first 30 days after each Juläine™ administration, in all treated participants.

    Time frame: First 30 days after each Juläine™ administration, in all treated participants.

  6. Incidence and severity of AEs up to 240 days.

    Incidence and severity of AEs up to 240 days after start of treatment in all treated participants.

    Time frame: Up to 240 days after start of treatment in all treated participants.

  7. Incidence and severity of AEs up to 480 days

    Incidence and severity of AEs up to 480 days after start of treatment in the immediate-start group.

    Time frame: Up to 480 days after start of treatment in the immediate-start group.

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jun 2027; primary completion for Jan 2028, 7 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start Oct 2026 → Jun 2027, primary completion Apr 2027 → Jan 2028 and completion Jun 2027 → Jan 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2025
First posted
Jan 12, 2026
StartEst.
Jun 2027was Oct 2026
Primary completionEst.
Jan 2028was Apr 2027
CompletionEst.
Jan 2029was Jun 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2026→Jun 2027
Nov 16, 2026
Primary completion
Apr 2027→Jan 2028
Nov 16, 2026
Study completion
Jun 2027→Jan 2029
Nov 16, 2026
Eligibility
1 exclusion criterion edited, 4 added, 1 removed
What changed in the criteria
Exclusion criteria
  • AddedHistory of thrombosis in the lower limbs.
  • AddedPrevious treatment with fillers, suspension threads, or fat injection in the treatment area within 18 months before randomization.
  • EditedAesthetic procedure onPrevious aesthetic procedures in the buttocks (including fillerstreatment area, elevation wires,including radiofrequency, ultrasound, cryotherapy, fat injection, neurotoxin, laser or light treatment, or chemical peel), within 6six months prior tobefore randomization.
  • AddedPrevious topical or home therapy for cellulite in the treatment area within three months before randomization.
  • RemovedExtensive tattoos covering >50% of the total gluteal area.
  • AddedPresence of any skin or local condition in the treatment area that could interfere with treatment administration, participant safety, or evaluation of study endpoints, including scars, fibrosis, tattoos, skin-pigmentation alterations, inflammation, lymphedema, or lipedema.
Nov 16, 2026
Secondary outcomes
3 edited, 1 time frame changed, 1 description edited
What changed in the outcomes
  • EditedIncidence and severity of expected local injection-site reactionsAdverse events in the first 30 daysTime frame: First 30 days after each Juläine™ administration, in all treated participants.
  • EditedIncidence and severity of AEs (excluding expected local post-injection reactions) up to 240 days.Time frame: Up to 240 days after start of treatment in all treated participants.
  • EditedIncidence and severity of AEs (excluding expected local post-injection reactions) up to 480 daysTime frame: Up to 480 days after start of treatment in the immediate-start group.
  • Time frameProportion of adverse events (AEs)Occurring up to 240 days after the start of treatment, in both treatment groups. → Occurring up to 240 days after the start of treatment, in both groups.
  • DescriptionProportion of adverse events (AEs): how it is measured was reworded
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Start date Oct 2026→Jun 2027
    Primary completion Apr 2027→Jan 2028
    Study completion Jun 2027→Jan 2029
    Eligibility 1 exclusion criterion edited, 4 added, 1 removed
    What changed in the criteria
    Exclusion criteria
    • AddedHistory of thrombosis in the lower limbs.
    • AddedPrevious treatment with fillers, suspension threads, or fat injection in the treatment area within 18 months before randomization.
    • EditedAesthetic procedure onPrevious aesthetic procedures in the buttocks (including fillerstreatment area, elevation wires,including radiofrequency, ultrasound, cryotherapy, fat injection, neurotoxin, laser or light treatment, or chemical peel), within 6six months prior tobefore randomization.
    • AddedPrevious topical or home therapy for cellulite in the treatment area within three months before randomization.
    • RemovedExtensive tattoos covering >50% of the total gluteal area.
    • AddedPresence of any skin or local condition in the treatment area that could interfere with treatment administration, participant safety, or evaluation of study endpoints, including scars, fibrosis, tattoos, skin-pigmentation alterations, inflammation, lymphedema, or lipedema.
    Secondary outcomes 3 edited, 1 time frame changed, 1 description edited
    What changed in the outcomes
    • EditedIncidence and severity of expected local injection-site reactionsAdverse events in the first 30 daysTime frame: First 30 days after each Juläine™ administration, in all treated participants.
    • EditedIncidence and severity of AEs (excluding expected local post-injection reactions) up to 240 days.Time frame: Up to 240 days after start of treatment in all treated participants.
    • EditedIncidence and severity of AEs (excluding expected local post-injection reactions) up to 480 daysTime frame: Up to 480 days after start of treatment in the immediate-start group.
    • Time frameProportion of adverse events (AEs)Occurring up to 240 days after the start of treatment, in both treatment groups. → Occurring up to 240 days after the start of treatment, in both groups.
    • DescriptionProportion of adverse events (AEs): how it is measured was reworded
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07332650
Lead sponsor
Nordberg Medical AB
Responsible party
Sponsor
First posted
Jan 12, 2026
Start date
Jun 2027 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Nov 16, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion